AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8639252 — intervention group
Group type: COMPARATOR
Intervention: CyA (4 mg/kg per day), prednisolone, and azathioprine
Number of subjects: 147
Study 1320241 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 52
Study 1320241 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 52
Study 30970186 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat 12 mg per day
Number of subjects: 1454
Study 30970186 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat 40 mg per day
Number of subjects: 1454
Study 30970186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1454
Study 30970186 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat groups
Number of subjects: 1454
Study 28620677 — intervention group
Group type: EXPERIMENTAL
Intervention: LEB + peloid therapy (5 days a week for 2 weeks)
Number of subjects: 75
Study 28620677 — intervention group
Group type: COMPARATOR
Intervention: LEB treatment alone
Number of subjects: 75
Study 25124939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel‐S10 once daily (n = 53)
Number of subjects: 165
Study 25124939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel‐S10 twice daily (n = 51)
Number of subjects: 165
Study 25124939 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily (n = 25)
Number of subjects: 165
Study 25124939 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily (n = 28)
Number of subjects: 165
Study 25124939 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerability of Oleogel‐S10
Number of subjects: 165
Study 25124939 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-assessed tolerability of Oleogel‐S10
Number of subjects: 165
Study 22863599 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0
Study 22863599 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched)
Number of subjects: 0
Study 21369817 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day suprapubic catheterization
Number of subjects: 179
Study 21369817 — intervention group
Group type: COMPARATOR
Intervention: 3-day suprapubic catheterization
Number of subjects: 179
Study 19023654 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P
Number of subjects: 59
Study 17531632 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesylate 500 mg administered within 1 hour before ERCP (group A, 203 patients)
Number of subjects: 608
Study 17531632 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesylate 500 mg administered within 1 hour after ERCP (group B, 203 patients)
Number of subjects: 608
Study 17531632 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (group C, 202 patients)
Number of subjects: 608
Study 15206691 — intervention group
Group type: EXPERIMENTAL
Intervention: polyethylene glycol interferon‐ribavirin‐amantadine
Number of subjects: 37
Study 15206691 — intervention group
Group type: EXPERIMENTAL
Intervention: polyethylene glycol interferon‐ribavirin
Number of subjects: 37
Study 11468500 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive counseling style
Number of subjects: 249
Study 11468500 — intervention group
Group type: COMPARATOR
Intervention: Controlling counseling style
Number of subjects: 249
Study 11468500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both styles
Number of subjects: 249
Study 10420072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin, Fragmin(R), 10,000 IU s.c. once daily)
Number of subjects: 654
Study 10420072 — intervention group
Group type: COMPARATOR
Intervention: Coumarin therapy
Number of subjects: 654
Study 8306683 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% medium-chain/50% long-chain triglycerides
Number of subjects: 6
Study 8306683 — intervention group
Group type: COMPARATOR
Intervention: 100% long-chain triglycerides
Number of subjects: 6
Study 3189214 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60,000 micrograms RE)
Number of subjects: 2012
Study 3189214 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2012
Study 29741420 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 53
Study 29741420 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 53
Study 28339668 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV4 booster dose
Number of subjects: 174
Study 26296299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46
Study 26296299 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (control)
Number of subjects: 46
Study 22882249 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) 12 IU
Number of subjects: 16
Study 22882249 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) 24 IU
Number of subjects: 16
Study 22882249 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) (all doses)
Number of subjects: 16
Study 22882249 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI) 12 IU
Number of subjects: 16
Study 22882249 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI) 24 IU
Number of subjects: 16
Study 21892586 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CECT 7315/7316
Number of subjects: 0
Study 21892586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19647104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation for one year
Number of subjects: 179
Study 19647104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 17958626 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan soap
Number of subjects: 224
Study 17958626 — intervention group
Group type: COMPARATOR
Intervention: Regular soap (placebo)
Number of subjects: 224
Study 14706125 — intervention group
Group type: EXPERIMENTAL
Intervention: Megace OS (400 mg daily for 63 days)
Number of subjects: 17
Study 14706125 — intervention group
Group type: COMPARATOR
Intervention: Usual NH care
Number of subjects: 17
Study 11593128 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based anesthetic
Number of subjects: 720
Study 11593128 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, fentanyl, and alfentanil as supplemental agents
Number of subjects: 720
Study 9159839 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 19
Study 9159839 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly Intermittent Peritoneal Dialysis (NIPD)
Number of subjects: 19
Study 9159839 — intervention group
Group type: COMPARATOR
Intervention: Both CAPD and NIPD
Number of subjects: 19
Study 7950196 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinkening
Number of subjects: 31
Study 7950196 — intervention group
Group type: COMPARATOR
Intervention: Persantin and Aspirin
Number of subjects: 31
Study 2888606 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Timentin
Number of subjects: 203
Study 2888606 — intervention group
Group type: COMPARATOR
Intervention: Oral tinidazole
Number of subjects: 203
Study 31622389 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP+ program
Number of subjects: 17
Study 28491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge on contraception
Number of subjects: 300
Study 28491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of knowledge
Number of subjects: 300
Study 28491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active students
Number of subjects: 300
Study 28491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive utilization
Number of subjects: 300
Study 28491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of sexual debut
Number of subjects: 300
Study 28491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned sexual debuts
Number of subjects: 300
Study 28491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group for sexual debut
Number of subjects: 300
Study 25329142 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone
Number of subjects: 0
Study 25329142 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine (Trilexis) patch
Number of subjects: 0
Study 23361937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) TKA
Number of subjects: 60
Study 23361937 — intervention group
Group type: COMPARATOR
Intervention: Cruciate-substituting (PS) TKA
Number of subjects: 60
Study 24590636 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (YG)
Number of subjects: 163
Study 24590636 — intervention group
Group type: COMPARATOR
Intervention: Stretching (ST)
Number of subjects: 163
Study 24590636 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 163
Study 19998192 — intervention group
Group type: COMPARATOR
Intervention: Active controlled trials (ACTs)
Number of subjects: 0
Study 19998192 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials (PCTs)
Number of subjects: 0
Study 17403837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 99
Study 17403837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 15887218 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography-derived gross tumor volume (GTV) measurements by experienced readers (4 neuroradiologists and 4 radiation oncologists)
Number of subjects: 20
Study 11793004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarmed cotton blankets
Number of subjects: 298
Study 11793004 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective blanket with head covering over 1 prewarmed cotton blanket
Number of subjects: 298
Study 11793004 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-warm-air inflatable blanket
Number of subjects: 298
Study 11793004 — intervention group
Group type: COMPARATOR
Intervention: Nurses' preference
Number of subjects: 298
Study 9883300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-Nasal Nasal Spray 200 micrograms qd
Number of subjects: 377
Study 9883300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-Nasal Nasal Spray 400 micrograms qd
Number of subjects: 377
Study 9883300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd
Number of subjects: 377
Study 9883300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 8584771 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 100
Study 8584771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2213395 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/kg IVIG daily for 4 days
Number of subjects: 44
Study 2213395 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm/kg IVIG as a single dose
Number of subjects: 44
Study 485800 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Strength Training (CST)
Number of subjects: 16
Study 485800 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 16
Study 485800 — intervention group
Group type: COMPARATOR
Intervention: CST or Jogging (final 8 weeks)
Number of subjects: 16
Study 30417231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan for 12 weeks
Number of subjects: 56
Study 30417231 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 56
Study 28385543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (single doses)
Number of subjects: 0
Study 28385543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin with intravenous rifampin (inhibited condition)
Number of subjects: 0
Study 25281416 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.5 mg/day
Number of subjects: 180
Study 25281416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 25281416 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 1.0 mg/day
Number of subjects: 180
Study 23448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy for hypertension
Number of subjects: 6010
Study 23448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (male gender, living in a regional area) and clinical factors (history of antihypertensive therapy, increased plasma creatinine, lower pretreatment pulse pressure, in-study use of multiple BP-lowering drugs)
Number of subjects: 6010
Study 23448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking care from multiple doctors (aged >80 years)
Number of subjects: 6010
Study 21562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecognized Q‐wave myocardial infarction at baseline
Number of subjects: 669
Study 21562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecognized Q‐wave myocardial infarction at 2 years follow-up
Number of subjects: 669
Study 21562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent myocardial infarctions
Number of subjects: 669
Study 21562320 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident myocardial infarctions
Number of subjects: 669
Study 19748297 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 139
Study 19748297 — intervention group
Group type: COMPARATOR
Intervention: Thermoplasticized gutta-percha with AH Plus sealer
Number of subjects: 139
Study 17012426 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 0
Study 17012426 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 0
Study 15290658 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg (n = 5068)
Number of subjects: 11945
Study 15290658 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (n = 1243)
Number of subjects: 11945
Study 15290658 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (n = 3018)
Number of subjects: 11945
Study 15290658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg (n = 2616)
Number of subjects: 11945
Study 15290658 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 11945
Study 15290658 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent dysphagia (17% of patients)
Number of subjects: 11945
Study 12536732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of mitomycin C (MMC) 0.4 mg/ml for 1 minute
Number of subjects: 62
Study 12536732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 62
Study 9678108 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic OCs
Number of subjects: 0
Study 9678108 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic OCs
Number of subjects: 0
Study 9678108 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing OCs
Number of subjects: 0
Study 9678108 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic levonorgestrel/ethinylestradiol and triphasic norgestimate/ethinylestradiol
Number of subjects: 0
Study 9678108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (all preparations)
Number of subjects: 0
Study 9678108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (desogestrel/ethinylestradiol 150/20)
Number of subjects: 0
Study 9678108 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users)
Number of subjects: 0
Study 8382162 — intervention group
Group type: EXPERIMENTAL
Intervention: S (+) oxaprotiline CGP 12,104 A
Number of subjects: 0
Study 8382162 — intervention group
Group type: COMPARATOR
Intervention: alpha 2-adrenoceptor binding on intact human platelets
Number of subjects: 0
Study 3549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (doses that reduced resting heart rate by 25%)
Number of subjects: 99
Study 3549413 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 99
Study 3549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (for compliant patients)
Number of subjects: 99
Study 3549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (for Child's grade A patients)
Number of subjects: 99
Study 3549413 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 99
Study 29155195 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDU + ICI (10 µg alprostadil) repeated assessments (maximum of 3 rounds)
Number of subjects: 302
Study 29155195 — intervention group
Group type: COMPARATOR
Intervention: CDDU + ICI (10 µg alprostadil) before and after sexological counseling
Number of subjects: 302
Study 27581473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention based on Finnish nutrition and physical activity recommendations
Number of subjects: 506
Study 27581473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: Office systolic BP (SBP)
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h SBP
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: Office diastolic BP (DBP)
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h DBP
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: Day SBP
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: Office SBP
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: Day DBP
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-day BP (SBP)
Number of subjects: 592
Study 25050884 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-day BP (DBP)
Number of subjects: 592
Study 23333252 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐paratyrosine (AMPT)
Number of subjects: 49
Study 23333252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 21453791 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep It Off phone-based intervention focusing on weight-loss maintenance behaviors, including self-monitoring, weight reporting, feedback, and outreach.
Number of subjects: 0
Study 18638651 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with borderline personality disorder (BPD) with a history of high lethality suicide attempts
Number of subjects: 0
Study 18638651 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with borderline personality disorder (BPD) with a history of low lethality suicide attempts
Number of subjects: 0
Study 18638651 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency management approach for patients with BPD presenting with increased risk of suicide
Number of subjects: 0
Study 16930101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (3mg)
Number of subjects: 32
Study 16930101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12567389 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard postural drainage chest physiotherapy (SPT)
Number of subjects: 20
Study 12567389 — intervention group
Group type: COMPARATOR
Intervention: Modified physiotherapy regimen without head-down tilt (MPT)
Number of subjects: 20
Study 10680790 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (DAP), 20 mg three times daily for 6 days
Number of subjects: 26
Study 10680790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9375332 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 8
Study 9375332 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation rewarming with saturated air at approximately 43 degrees C
Number of subjects: 8
Study 9375332 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous rewarming (control)
Number of subjects: 8
Study 7654578 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine spray 0.5%
Number of subjects: 382
Study 7654578 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine spray 2%
Number of subjects: 382
Study 7654578 — intervention group
Group type: COMPARATOR
Intervention: Amorolfine cream 0.5%
Number of subjects: 382
Study 7654578 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine spray (both concentrations)
Number of subjects: 382
Study 3300174 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy (CSII)
Number of subjects: 40
Study 3300174 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 40
Study 3300174 — intervention group
Group type: COMPARATOR
Intervention: Declined pump treatment
Number of subjects: 40
Study 29784057 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) tapering first
Number of subjects: 78
Study 29784057 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (AVP) tapering first
Number of subjects: 78
Study 27211885 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 78
Study 27211885 — intervention group
Group type: COMPARATOR
Intervention: Routine oral care with thymol
Number of subjects: 78
Study 24328800 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MHI
Number of subjects: 91
Study 24328800 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of consciousness (within MHI)
Number of subjects: 91
Study 24328800 — intervention group
Group type: COMPARATOR
Intervention: No-MHI
Number of subjects: 91
Study 23539700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearings
Number of subjects: 539
Study 23539700 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearings
Number of subjects: 539
Study 20602016 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam‐beta‐cyclodextrin
Number of subjects: 75
Study 20602016 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg piroxicam‐beta‐cyclodextrin
Number of subjects: 75
Study 20602016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 18955748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid drive-axis wheelchair
Number of subjects: 16
Study 18955748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rear drive-axis wheelchair
Number of subjects: 16